Company research
Inozyme Pharma, Inc.
CIK 1693011Updated Sep 24, 2026
Name history
Inozyme Pharma, LLC · through Jan 5, 2017
Filing activity
Latest filing
50 filings on record · SCHEDULE 13G/A, 15-12G, 4, EFFECT, 25-NSE, S-8 POS.
About the company
Inozyme Pharma is a clinical-stage biopharmaceutical company, with approximately 50 employees based in Boston. The company is dedicated to developing innovative therapeutics that target the PPi-Adenosine Pathway, a key regulator of bone health and blood vessel function. Disruptions in this pathway underlie a range of severe diseases, including ENPP1 Deficiency. Our lead investigational therapy, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy designed to restore pyrophosphate and adenosine levels. INZ-701 is currently in late-stage clinical development in ENPP1 Deficiency, with the potential to expand into additional indications where deficiencies in the Pyrophosphate-Adenosine Pathway contribute to disease pathology, including ABCC6 Deficiency and calciphylaxis. Through our pioneering work, we aim to transform treatment options for patients affected by these devastating conditions.
Recent filings
SCHEDULE 13G/A - filed by Beryl Capital Management LLC regarding Inozyme Pharma, Inc.
SCHEDULE 13G/A - filed by Rock Springs Capital Management LP regarding Inozyme Pharma, Inc.
SCHEDULE 13G/A - filed by Adage Capital Management, L.P. regarding Inozyme Pharma, Inc.
15-12G filing
4 filing
Show 5 more recent filings
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 123,182,000Source | 200,847,000Source | 139,195,000Source | 123,541,000Source |
| Property, Plant and Equipment, NetUSD | 784,000Source | 1,466,000Source | 2,018,000Source | 2,383,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 21,081,000Source | 34,588,000Source | 32,915,000Source | 23,316,000Source |
| Assets, CurrentUSD | 120,676,000Source | 196,250,000Source | 131,393,000Source | 115,342,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,278,000Source | 7,661,000Source | 3,527,000Source | 3,541,000Source |
| Operating Lease, Right-of-Use AssetUSD | 562,000Source | 1,126,000Source | 1,620,000Source | 2,053,000Source |
| Other Assets, NoncurrentUSD | — | — | 354,000Source | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 65,356,000Source | 60,368,000Source | 20,801,000Source | 14,273,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 6,000Source | 6,000Source | 4,000Source | 2,000Source |
| Retained Earnings (Accumulated Deficit)USD | -387,954,000Source | -285,930,000Source | -214,761,000Source | -147,700,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 69,000Source | 41,000Source | -205,000Source | 18,000Source |
| Stockholders' Equity Attributable to ParentUSD | 57,826,000Source | 140,479,000Source | 118,394,000Source | 109,268,000Source |
| Additional Paid in Capital, Common StockUSD | 445,705,000Source | 426,362,000Source | 333,356,000Source | 256,948,000Source |
| Liabilities and EquityUSD | 123,182,000Source | 200,847,000Source | 139,195,000Source | 123,541,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 33,898,000Source | 14,686,000Source | 14,715,000Source | 11,633,000Source |
| Operating Lease, Liability, CurrentUSD | 913,000Source | 910,000Source | 816,000Source | 731,000Source |
| Accounts Payable, CurrentUSD | 2,530,000Source | 1,166,000Source | 2,544,000Source | 2,394,000Source |
| Operating Lease, Liability, NoncurrentUSD | 0Source | 913,000Source | 1,823,000Source | 2,640,000Source |
| Other Liabilities, NoncurrentUSD | — | 0Source | 124,000Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 15,953,000Source | 12,610,000Source | 11,355,000Source | 8,508,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 113,100,000Source | 188,600,000Source | 127,900,000Source | 111,800,000Source |
| Long-term DebtUSD | 31,458,000Source | 44,769,000Source | 4,139,000Source | — |
| Short-term InvestmentsUSD | 92,006,000Source | 154,001,000Source | 94,951,000Source | 88,485,000Source |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -102,024,000Source | -71,169,000Source | -67,061,000Source | -56,624,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 7,945,000Source | 7,037,000Source | 7,672,000Source | 7,164,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 1,364,000Source | -1,378,000Source | 150,000Source | -675,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -91,907,000Source | -70,675,000Source | -57,761,000Source | -48,153,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 66,998,000Source | -53,646,000Source | -5,403,000Source | 42,796,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 62,000Source | 298,000Source | 410,000Source | 397,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 11,398,000Source | 125,969,000Source | 72,788,000Source | 609,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | 9,624,000Source | -4,748,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 4,350,000Source | 2,347,000Source | 170,000Source | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 7,945,000Source | 7,000,000Source | 7,700,000Source | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 113,100,000Source | 188,600,000Source | 127,900,000Source | 111,800,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | 0Source | 0Source | 0Source | 0Source |
| DepreciationUSD | 742,000Source | 833,000Source | 744,000Source | 674,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | 18,000Source | -26,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | -17,000Source | — |
| General and Administrative ExpenseUSD | 20,799,000Source | 20,798,000Source | 20,826,000Source | 18,926,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 5,558,000Source | — | — | — |
| Investment Income, InterestUSD | 7,666,000Source | 7,837,000Source | 1,933,000Source | 211,000Source |
| Net Income (Loss) Attributable to ParentUSD | -102,024,000Source | -71,169,000Source | -67,061,000Source | -56,624,000Source |
| Nonoperating Income (Expense)USD | 2,006,000Source | 4,476,000Source | 1,614,000Source | 22,000Source |
| Operating ExpensesUSD | 104,030,000Source | 75,645,000Source | 68,675,000Source | 56,646,000Source |
| Operating Lease, ExpenseUSD | 700,000Source | 900,000Source | 700,000Source | 700,000Source |
| Operating Lease, Impairment LossUSD | 564,000Source | 494,000Source | 433,000Source | 378,000Source |
| Other Nonoperating Income (Expense)USD | -102,000Source | -28,000Source | -319,000Source | -189,000Source |
| Proceeds from Issuance of Common StockUSD | 10,521,000Source | 85,647,000Source | 56,137,000Source | — |
| Proceeds from Issuance of Long-term DebtUSD | 0Source | 40,000,000Source | 4,050,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 596,000Source | 116,000Source | 359,000Source | 609,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -104,030,000Source | -75,645,000Source | -68,675,000Source | -56,646,000Source |
| Other Nonoperating Income (Expense)USD | -102,000Source | -28,000Source | -319,000Source | -189,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -102,024,000Source | -71,169,000Source | -67,061,000Source | -56,624,000Source |
| Earnings Per Share, BasicUSD per share | -1.62Source | -1.37Source | -1.78Source | — |
| Earnings Per Share, DilutedUSD per share | -1.62Source | -1.37Source | -1.78Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 62,811,814Source | 51,839,131Source | 37,763,168Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 62,811,814Source | 51,839,131Source | 37,763,168Source | — |
| Interest Expense (non-operating)USD | 5,558,000Source | — | — | — |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | 700,000Source | 800,000Source | 744,000Source | 674,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | 18,000Source | -26,000Source |
| General and Administrative ExpenseUSD | 20,799,000Source | 20,798,000Source | 20,826,000Source | 18,926,000Source |
| Interest ExpenseUSD | — | 3,333,000Source | — | — |
| Investment Income, InterestUSD | 7,666,000Source | 7,837,000Source | 1,933,000Source | 211,000Source |
| Management Fee ExpenseUSD | — | — | — | 400,000Source |
| Nonoperating Income (Expense)USD | 2,006,000Source | 4,476,000Source | 1,614,000Source | 22,000Source |
| Operating ExpensesUSD | 104,030,000Source | 75,645,000Source | 68,675,000Source | 56,646,000Source |
| Operating Lease, ExpenseUSD | 700,000Source | 900,000Source | 700,000Source | 700,000Source |
| Research and Development ExpenseUSD | 83,231,000Source | 54,847,000Source | 47,849,000Source | 37,720,000Source |